• Egetis posted Q2 revenue of SEK 17.4 million, up 23% from a year earlier.
• Quarterly loss widened to SEK 108.9 million; loss per share was SEK 0.2 before and after dilution.
• Cash rose to SEK 378.4 million at quarter-end; quarterly cash flow turned positive at SEK 230.2 million.
• FDA priority review of Emcitate NDA stayed on track for a Sept. 28, 2026 PDUFA decision; no advisory committee planned.
• Directed share issue raised SEK 350 million gross; U.S. Expanded Access Program covered 17 hospitals with about 60 patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Egetis Therapeutics AB (publ) published the original content used to generate this news brief on August 21, 2026, and is solely responsible for the information contained therein.